Glioblastoma (GBM) is a highly aggressive primary brain tumor that is especially difficult to treat. The tumor's ability to withstand hypoxia leads to enhanced cancer cell survival and therapy resistance, but also yields a microenvironment that is in many aspects unique within the human body, thus offering potential therapeutic opportunities. The spore-forming anaerobic bacterium Clostridium novyi-NT (C. novyi-NT) has the ability to propagate in tumor-generated hypoxia, leading to oncolysis.
IntroductIon
Approximately 3% of all cancer deaths are attributed to primary brain tumors [1] . Among those, glioblastoma multiforme (GBM), a grade IV astrocytoma arising from the glial tissue, is the most common (65%) and deadly primary brain malignancy [1] . As the "multiforme" component implies, GBM exhibits large variability at the histopathological level, with extensive necrotic regions intermixed with cell proliferation and infiltration [2] . GBMs are one of the most difficult cancer types to treat, with a 5-year survival rate of less than 5% [1] . This is so despite >600 clinical trials and multi-mode treatments that include surgical resection, local delivery of BCNU (Gliadel wafers), and concurrent chemoradiotherapy with temozolomide (TMZ) followed by adjuvant TMZ. Reasons for treatment failure are complex and include incomplete surgical excision due to the tumor's invasiveness as well as insufficient drug delivery to the remaining tumor cells [3] .
Unlike hematological cancers, most solid tumors and in particular GBM rapidly outgrow their vascular supply and develop tumor hypoxia, complicating treatment with traditional cancer therapies [4] .The poor tumor vascular supply inevitably limits the delivery of systemically administered chemotherapeutic drugs and reduces the effectiveness of radiotherapy [5] . Tumor hypoxia has a central role in tumor metabolism, progression, metastasis, and immune evasion [4] . Though conceptually a promising target, a means to successfully utilize tumor hypoxia has not yet been achieved. Previous efforts focusing on molecular targeting with small molecules has had only limited success [6] .
Another approach to exploit the hypoxic nature of the tumor environment involves anaerobic bacteria. The oncolytic ability of bacteria has been recognized since the early 1800s, as exemplified by the development of Coley's vaccine [7] . Various species of Clostridium, Salmonella, Escherichia, Bifidobacterium and Listeria have all been considered for this purpose [8] . One more recently recognized species is Clostridium novyi, which in its therapeutic form is devoid of the lethal alpha toxin gene, termed C. novyi-NT [9] . C. novyi is a highly mobile, spore-forming bacterium that is exquisitely sensitive to oxygen. As an obligate anerobe, vegetative forms cannot survive in oxygen and bacterial spores can only germinate in hypoxic conditions [10] . Previous studies showed that a single dose of C. novyi-NT spores injected intravenously in syngeneic tumor-bearing animals often led to localized tumor necrosis and oncolysis, leading to cures in up to one-third of treated animals, without excessive toxicity [11, 12] .
In this work we show that treatment of GBMbearing animals with C. novyi-NT spores results in localized germination, tumor destruction and a significant survival benefit. These encouraging results suggest that the approach should be developed further.
results

I.V. injected C. novyi-nt spores increase survival in rodent glioblastoma models
To assess the potential value of C. novyi-NT bacteriolytic therapy for intracranial malignancies, we used two different rodent orthotopic GBM models. Both models were highly invasive and known to form intratumoral necrosis as well as hypoxia in rodents (Fig.  1A-L) , characteristics found in their human counterparts.
The GBM neurosphere cell line 060919 was grown from a surgically resected GBM in serum-free media [13] . 060916 cells were implanted intracranially and allowed to grown until day 25 when the rats were injected with 3x10 8 C. novyi-NT spores via tail vein. Therapy with C. novyi-NT resulted in a significant overall survival improvement and one long-term surviving rat of 10 that were treated ( Fig. 2A) . Bacterial germination began within 12 hours after injection and was florid by 24 hours, as evidenced by the presence of many vegetative bacteria on histological sections of the tumor. Successful tumor lysis was evident by the dramatic decline in luciferase signal (>90%) in the first 48 hours and the rapid reduction of circulating human DNA, both of which served as indicators of tumor burden (Fig. 2B-D) .
Commonly observed side effects of bacteriolytic therapy included lethargy, brain edema and increased intracranial pressure (ICP). We found that increased ICP was a major cause of death if not detected early and treated aggressively with steroids and antibiotics. Animals with ICPs ≤ 40 mmHg readily responded to medical management, measured by an immediate ICP reduction, and fully recovered (Fig. 2E) . Animals with ICPs of >45 mmHg did not respond to medical therapy and subsequently died.
To determine whether these results could be reproduced in an immune-competent rodent model, we used F98 cells that were originally produced by IV administration of N-ethyl-N-nitrosourea, a highly potent mutagen, into pregnant Fisher F344 rats that are refractory to a number of chemotherapeutics. Treatment of this aggressive intracerebral tumor with C. novyi-NT significantly prolonged survival (Fig. 3A) . Similar to the 060919 model, a dramatic reduction in luciferase activity was present 48 hours after treatment compared to the untreated controls (Fig. 3B, C) . However, tumor eradication was incomplete, particularly in the less hypoxic tumor rim, and tumors eventually regrew.
Histological analysis of brain sections of both highgrade glioma models revealed that bacterial germination was precisely localized to the tumor and involved the tumor body as well as distant tumor satellites, while the normal brain parenchyma was unaffected (Fig. 4A , B, D, E). Within tumors, vegetative bacterial distribution was not random; it was strictly co-localized with TUNEL positive tumor cells (red) (Fig. 4C, F) . Importantly, germination was not limited to the larger tumor mass and extended to stem-like protrusions from the main tumor, as well as microscopic distant tumor satellites and tumor vessels (Fig. 4B, E) . Bacterial infection was accompanied by a striking accumulation of host inflammatory cells, predominantly neutrophils at the periphery, presumably limiting bacterial spread (Fig. 4G , H).
combination with liposomal doxorubicin has synergistic effects
Though the effect of C. novyi-NT treatment is dramatic, long-term survival is rarely achieved and hence, a combination with other complementary chemotherapeutic agents could prove useful. For this purpose, we first determined the half-maximal inhibitory concentrations (IC 50 ) of seven commonly used chemotherapeutic agents of F98 cells in vitro. The most potent proved to be doxorubicin, a DNA intercalating substance, with an IC 50 of 0.14μM (Fig. 5A) . A liposomal formulation of doxorubicin (Lip-DXR) has previously been reported to enhance the anti-tumor efficacy of C. novyi-NT and may act as a depot for sustainable drug release [14] . In the syngeneic F98 GBM model, the combination of Lip-DXR and C. novyi-NT increased the survival modestly compared to C. novyi-NT alone ( DXR had improved tumor clearance, as exemplified by the lower number of viable tumor cells, particularly in the periphery (Fig. 5C, D) .
C. novyi-NT germination is specific to tumor generated hypoxia and necrosis
To determine if C. novyi-NT germination is specific to tumor associated hypoxia and necrosis, we established a cerebral ischemic rat middle cerebral artery occlusion stroke model. A large middle cerebral artery (MCA) infarct was created in normal athymic rats by transiently occluding the MCA while ligating the right internal carotid artery for 2 hours, thereby decreasing MCA blood flow by 70-90% (Fig. 6A, B) . TTC and HIF-1α staining confirmed the infarction and hypoxia in the brain (Fig. 6C) .
Subsequently, 3x10
8 green-fluorescently labeled C. novyi-NT spores were injected into the tail vein and the animals observed for 5 days. Histopathological examination of the brains on day 5 demonstrated that, while the rats had large cerebral infarcts with extensive areas of necrosis, there was no histopathological or molecular-biologic evidence of bacterial colonization within or surrounding the lesions. C. novyi-NT spores (but not germinated bacteria) were found in the necrotic areas of the stroke, formally demonstrating that the absence of bacterial germination was not caused by the failure of spore delivery (Fig. 7A,  B) .
To prove that a sufficient degree of hypoxic injury was achieved in the stoke model, sections were stained with HIF-1α via immunofluorescence. HIF-1α is a key component of the cells' response to hypoxia, and the oxygen-labile HIF-1α protein is known to be induced in [15] . The numbers of HIF-1α positive cells in the necrotic regions of tumors and strokes were similar, while bacterial germination was only evident in the tumors (Fig. 7A) .
dIscussIon
Despite progress in the understanding, diagnosis and therapy of brain cancers, GBM remains a lethal disease. Complete surgical excision is nearly always impossible as a result of local infiltration and anatomical limitations, thus leading inevitably to tumor relapse [16] . Attempts to target common genetic defects in GBM have failed to provide long-term survival and have not replaced nontargeted approaches with chemotherapy and radiation [17] . Here, we investigated if spore-forming bacterium C. novyi-NT targeting the cancer's hypoxia might be technically feasible and beneficial in preclinical models of GBM.
Hypoxia is a critical aspect of glioblastoma biology and the development of resistance to chemotherapy and radiotherapy [4] . Though this hypoxic state represents a major therapeutic challenge, it also provides a potential opportunity. Anaerobic bacteria have evolved to thrive in the hypoxic environment and fortuitously some possess several key features that make them ideal anti-tumor agents [8] . The toxin-deleted strain C. novyi-NT appears to be particularly promising because: 1) bacteria germinate specifically in tumor-generated hypoxia but not in hypoxia generated by stroke (Fig. 6 ) or myocardial infarctions [12] , (2) cytotoxicity is limited to the tumor while sparing adjacent normal tissues, and (3) vegetative C. novyi-NT are highly mobile, rapidly infecting the entire tumor. A single intravenous injection of C. novyi-NT spores into glioma-bearing rats resulted in florid germination C. novyi-NT's tumor-specificity is probably a result of the fact that hypoxia-driven necrosis in cancers may generate a steeper oxygen pressure gradient (dynamic hypoxia) compared to infarcted tissues (static hypoxia) with higher oxygen pressures [18] .
Although the blood-brain barrier (BBB) normally protects the central nervous system from invading microorganisms, brain tumors or other inflammatory conditions can compromise its integrity and result in local breakdown of the BBB. This along with the fragile and leaky tumor vasculature manifesting in intratumoral hemorrhages can favor C. novyi-NT spore accumulation in an ischemic stroke (left) and a F98 rat glioma (right). Both lesions, the stroke and brain tumor, have strong immunoreactivity for HIF-1α (red). However, despite the presence of C. novyi-NT spores (green, white arrow) in areas of the ischemic infarct, they did not germinate, as indicated by the absence of green staining. Spores in tumoral hypoxia were able to germinate (green) and co-localized with hypoxiapositive tumor cells. DAPI is shown in blue. (B) Consistent with the immunofluorescent data, PCR confirmed that vegetative bacteria were only present in the glioma but not in the infarct, although C. novyi-NT spores were found in both lesions. the brain tumor bed. In addition, systemically administered C. novyi-NT spores could use the 'Trojan horse' method of entry by traveling in leukocytes. In this scenario C. novyi-NT spores are ingested by leukocytes where they remain dormant and once the infected leukocytes pass through the BBB, the spores escape as shown with Clostridium difficile [19] .
With the advances in synthetic biology, there is a renewed interest in bacterial therapies for cancer [8] . Though the use of an attenuated strain of C. novyi (i.e., C. novyi-NT) reduces treatment-related toxicity, safety remains the major hurdle in clinical use [20] . In our study, the majority of rats treated with C. novyi-NT developed lethargy and signs of increased intracranial pressure due to local inflammation-driven edema that were medically manageable with the use of steroids and antibiotics, but the dangers of treating rats with intracranial tumors were evident. Similar observations were made by Diaz using tumor-bearing mice and rabbits, where edema and reversible inflammatory changes in the spleen, liver and adrenal glands were observed during spore treatment [12] . Most recently, Roberts reported a study in which ten pet dogs with spontaneous soft-tissue sarcomas treated with intratumoral injections of C. novyi-NT spores developed local edema and abscesses that required antibiotics or surgical excision of the infected tissues [21] .
Truly effective cancer therapy will indubitably require a combination of multiple treatment modalities. Intravenous administration of C. novyi-NT enhances the effect of chemotherapy, particularly of hypoxia-enhancing agents, and radiation [11] . Consistent with those data, treatment with C. novyi-NT and liposomal doxorubicin resulted in a slightly increased survival benefit due to enhanced cytotoxicity [14] . It could also be valuable to combine C. novyi-NT with immune-checkpoint inhibitors. It has been demonstrated that long-term response to C. novyi-NT involves an immunologic T-cell based recognition that likely includes tumor antigens [22] .
In summary, bacteriolytic therapy with the anaerobic spore forming bacterium C. novyi-NT is capable of precisely localizing to tumors and mediating robust tumoricidal activity with manageable side effects in two highly aggressive GBM models. The results provide a rationale for continuing to develop this approach for potential application in humans.
MAterIAls And MetHods cell lines and tissue culture
Human GBM neurosphere line 060919 was grown in NeuroCult NS-A basal medium containing NeuroCult NS-A proliferation supplements (Stem Cell Technologies), 20 ng/mL epidermal growth factor (PeproTech), 10 ng/mL basic fibroblast growth factor (PeproTech), and 4 μg/mL heparin (Stem Cell Technologies). Rat F98 glioma cell line was maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics. Both cell lines, 060910 and F98, were transfected with a luciferase construct via lentivirus (0609191-luc, F98-luc).
brain tumor models
6-week-old female F344 Fisher rats (weight 100-150 gram) and athymic nude rats were purchased from the National Cancer Institute (Bethesda, MD). For the implantation procedure, rats were anesthetized via intraperitoneal (i.p) injection composed of ketamine hydrochloride (75 mg/kg; 100 mg/mL; ketamine HCl; Abbot Laboratories), xylazine (7.5 mg/kg; 100 mg/ mL; Xyla-ject; Phoenix Pharmaceutical), and ethanol (14.25%) in a sterile 0.9% NaCl solution. Following, 500,000 human GBM 060919 neurosphere cells infected with luciferase lentivirus were stereotactically implanted into the right frontal lobe located 3 mm lateral and 2 mm anterior to the bregma of athymic rats as previously described [23] . 20,000 F98-luc cells were stereotactically implanted into F344 Fisher rats using the same parameters. The tumors were allowed to grow until day 25 (060919) or 15 (F98), when 3x10 8 C. novyi-NT spores, produced as previously described [9] , were injected into the tail vein. In addition, a subset of animals received liposomal doxorubicin (Doxil, Lip-DXR, Janssen, Titusville, NJ), 5 mg/kg i.p. at the time of spore injection. Pre-and posttreatment tumor sizes were assessed with a Xenogen instrument after intraperitoneal injection of 50mg/ kg D-luciferin potassium salt per rat. During the first two days of bacterial therapy, rats were placed on 10 mg/kg/day dexamethasone i.p. to minimize the risk of postoperative edema. Control rats were stereotactically injected with the same volume of phosphate-buffered saline (PBS) and treated with dexamethasone (10 mg/ kg per day) for the first 2 days. Animals were observed daily for any signs of deterioration, lethargy, neurotoxicity, or pain in accordance with the Johns Hopkins Animal Care and Use Guidelines. If symptoms of distress were present, supportive therapy with hydration and antibiotic metronidazole (loading dose of 15 mg/kg i.p. followed by 10 mg/kg every 12 hours as maintenance) was initiated and continued for a 7-day period. If symptoms persisted and/or resulted in debilitation, moribund animals were euthanized according to protocol. The anti-tumor efficacy of C. novyi-NT treatment was assessed with KaplanMeier survival curves, Xenogen results, and the degree of tumor burden on post-mortem brain sections. For the latter purpose, brains were harvested post-mortem, placed in formalin, and embedded in paraffin for additional pathological studies. Gram-stained slides, counter-stained with safranin, and H&E-slides were prepared according to www.impactjournals.com/oncotarget routine histopathologic practices.
Intracranial Pressure (IcP) measurement
Intracranial pressure was measured with an intraventricular catheter in athymic nude rats. In brief, a burrhole was drilled 1 mm posterior and 1 mm lateral to the bregma. Subsequently, a 2.5 mm long probe modified from a G20 needle by shortening the shaft and removing the plastic adaptor was inserted into the right lateral ventricle and glued to the skull. For measurements, a PE10 catheter was attached to the G20 needle, flashed with normal saline and connected with a Life Scope 6 pressure monitor (Nihon Kohden Corporation). The monitor was reset to zero before attaching to the probe.
Stroke model
The intraluminal filament model of middle cerebral artery occlusion (MCAO) was used to induce focal ischemic injury to the brain in athymic nude rats [24] . Briefly, after anesthetization a laser-Doppler flow (LDF) probe was placed on the skull of the nude rat to monitor the perfusion. To induce a right-sided ischemic stroke, the right common carotid artery (CCA) was exposed through a submandibular midline incision. Then, the proximal end of the CCA was temporarily ligated and a 4-0 nylon monofilament was inserted into the internal carotid artery (ICA) and advanced past the CCA bifurcation to the origin of the MCA. After two hours, reperfusion of the right MCA was achieved by withdrawal of the filament and release of the CCA ligature. Animals were allowed to recover for 24 hours before 3x10
8 FITC-fluorescent C. novyi-NT spores, produced as described by Diaz [12] , were injected into the tail vein. Animals were sacrificed after 5 days. Post-mortem, brains were removed and incubated with 2,3,5-triphenyltetrazolium chloride (TTC) for 30 minutes to visualize the hypoxic areas as described [25] . Additionally, brains were embedded in paraffin for further histological analyses.
nested Pcr for detection of vegetative forms of c. novyi-nt from brains 75 mg of fresh lesional brain tissue was harvested from sacrificed animals with strokes or GBM. The preparation of the tissue followed previous reports by Bettegowda [26] . RNA was prepared by homogenization of the dissected tissue in a glass homogenizer containing a ten-fold volume of ice-cold RNAwiz buffer (Ambion) followed by 12-cycle homogenization with Zirconia beads (Biospec) for 10 min at 4 °C to ensure disruption of the spores. RNA was isolated using the RNA Total Kit (Promega) and quantified with a UV spectrophotometer.
First-strand cDNA was synthesized from total RNA using random oligonucleotides as primers and the SuperScript First-Strand Synthesis System (Invitrogen). Synthesized cDNA was then used for a nested PCR to detect C. novyi-NT's growth phase specific genes. The first run used primer pair (CCATAGCAATAAATCTTCCCTC and CATCTAAGCTTGAAACGTGTAG) targeting NT01CX2304, an indicator for vegetative bacteria, as well as primer pair (GCTAGTAAATGTGGATTTACTCC and ATTTCAGATGGTTCTGTGGTAG) targeting NT01CX2376, a marker for spores [16] . In the second run primer pair (CTCTTAATACCTCTTTCCCTTC and GTGTTTGTCATATGCTACTTCC) for NT01CX2304 and (CCTGGTAGTAACTCTGAAGTTA and GTGGTAGGTTCAAATCTACCAA) for NT01CX2376 were used. All PCR products were checked in 1.5% (wt/ vol) agarose electrophoresis with 1× Tris-borate-EDTA (TBE) buffer, stained with ethidium bromide (0.2 μg/mL). DNA bands were detected under UV light.
Human LINE-1 (hLINE-1) quantification hLINE-1 was quantified in the blood from tumorbearing athymic nude rats to monitor the tumor burden as described [27] . Briefly, approximately 50 µl of blood were collected at various time points and DNA was purified according to the instructions of the Qiagen DNA purification kit (Qiagen, Valencia, CA). Quantitative PCR employed 0. 
Histological staining
Post-mortem brains were fixed with 10% buffered formalin and paraffin-embedded. For histological analysis, sections were deparaffinized with xylene, and rehydrated in a graded ethanol series.
tunel staining
TdT-mediated dUTP nick end labeling was performed using the DeadEnd™ TUNEL system, according to the manufacturer's instructions (Promega, Madison, WI).
Immunohistochemistry/Immunofluorescence
Immunohistochemical and immunofluorescence experiments were carried out as previously described [28] . Briefly, non-specific binding sites were blocked by incubation with 10% goat serum in PBS for 1 h at room temperature. The following primary antibodies were used: HIF-1 alpha (Abcam), CD45 (Abcam), C. novyi-NT antibody [22] . Omission of the primary antibody served as the negative control. For immunohistochemical detection, HRP-linked anti-rabbit or anti-mouse secondary antibodies were used (EnVision™ kit, DAKO). Visualization with DAB was performed according to the manufacturer's instructions (DAKO, Carpinteria, CA). For immunofluorescence detection the following secondary antibodies were applied: anti-rabbit Alexa 488 or anti-mouse Alexa 594 (Invitrogen). Sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, Vector Laboratories), and examined under the microscope.
statistical analysis
Results are presented as a mean value ± standard deviation. P values were determined by a Mantel-Cox test and P values < 0.05 were deemed as statistically significant. Data were analyzed by GraphPad Prism, version 5.0. 
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